Facial Hair in Women: Which Labs You Need and What to Do Next

What Is Hirsutism and Why Does It Happen to Women?

Hirsutism means coarse, pigmented, terminal hair growing in a male-pattern distribution on a woman's face, jaw, chin, upper lip, or neck. It is not the same as hypertrichosis, which is generalized fine hair growth all over the body. The distinction matters because hirsutism almost always reflects androgen excess or heightened follicle sensitivity to androgens, while hypertrichosis usually does not.

The hair follicle responds to dihydrotestosterone (DHT), the locally converted form of testosterone. When circulating androgens rise, or when the enzyme 5-alpha reductase in the follicle converts testosterone to DHT at a higher rate, vellus (fine, colorless) facial hairs transform into coarse terminal hairs. About 5-10% of reproductive-age women meet the clinical definition of hirsutism, making it one of the most common endocrine complaints in women's health.

The Ferriman-Gallwey Score: How Clinicians Measure It

The modified Ferriman-Gallwey (mFG) score rates nine body areas on a scale of 0 to 4. A total score of 4 or above is considered hirsutism in most U.S. Guidelines, though The Endocrine Society's 2018 clinical practice guideline notes that the cutoff varies by ethnicity: East Asian women often score lower despite significant androgen excess, while Mediterranean and South Asian women may score higher at baseline. Your clinician may use photographs or a standardized grid to track change over time.

Why Ethnicity Changes the Interpretation

Follicle sensitivity to androgens varies across populations. This means two women with identical testosterone levels can show very different amounts of facial hair. Research published in the Journal of Clinical Endocrinology and Metabolism confirmed that ethnicity-adjusted mFG cutoffs improve diagnostic accuracy. If you are East Asian and notice new coarse hairs on your chin, do not let a "normal" mFG score dismiss your concern.

The Most Common Causes by Life Stage

Facial hair does not have a single cause. Understanding where you are in your reproductive life shapes which diagnosis is most likely.

Reproductive Years (Ages 13-45)

Polycystic ovary syndrome (PCOS) is the leading cause, accounting for 72-82% of hirsutism cases in women of reproductive age. PCOS elevates luteinizing hormone (LH) and drives the ovarian theca cells to overproduce testosterone. You do not need to have cysts on an ultrasound to have PCOS; two of three Rotterdam criteria (irregular cycles, androgen excess, or polycystic ovarian morphology) are sufficient for diagnosis.

Nonclassical congenital adrenal hyperplasia (NCAH) caused by 21-hydroxylase deficiency mimics PCOS almost exactly. It affects approximately 1-2% of hyperandrogenic women and is more common in Ashkenazi Jewish, Hispanic, and Eastern European women. A fasting early-morning 17-hydroxyprogesterone (17-OHP) level above 200 ng/dL warrants an ACTH stimulation test to confirm.

Idiopathic hirsutism means labs are entirely normal. The follicle is simply more sensitive to normal androgen levels. This accounts for roughly 15-20% of cases.

Medications that can trigger or worsen facial hair include valproic acid, anabolic steroids, danazol, cyclosporine, minoxidil, and progestins with high androgenic activity (such as levonorgestrel or norgestrel in some combined pills).

Trying to Conceive or Pregnant

New, rapidly progressive facial hair during pregnancy should be taken seriously. An androgen-secreting ovarian or adrenal tumor, though rare, can declare itself during pregnancy. A 2019 ACOG Practice Bulletin recommends urgent evaluation if hirsutism onset is abrupt or accompanied by virilization signs (clitoral enlargement, deepening voice, significant muscle mass change).

Perimenopause

The transition typically begins in the mid-to-late 40s. As estrogen levels fluctuate and eventually fall, testosterone's relative influence on follicles increases. Many women notice their first chin hairs in perimenopause even though their total testosterone has not risen much. The ratio shifts; estrogen is no longer counterbalancing androgen signaling at the follicle level.

Post-Menopause

After menopause, ovarian estrogen production drops sharply, but the ovarian stroma continues producing testosterone for years. Studies using mass-spectrometry-based assays show that post-menopausal women retain measurable testosterone, sometimes enough to drive continued or worsening facial hair. If hirsutism is new and rapid-onset after menopause, an androgen-secreting tumor must be ruled out.

Which Labs Do You Actually Need?

A targeted panel answers the key question: where is the androgen coming from?

First-Line Blood Tests

| Test | What It Tells You | Timing | |---|---|---| | Total testosterone | Overall androgen burden | Fasting, cycle day 2-5 if cycling | | Free testosterone | Bioavailable androgen (more sensitive) | Same draw | | DHEA-S | Adrenal androgen production | Any day | | 17-OHP | Screens for NCAH | Fasting, early morning | | Prolactin | Rules out hyperprolactinemia | Fasting | | TSH | Hypothyroidism can worsen hair changes | Any day |

The Endocrine Society guideline recommends measuring total and free testosterone as the first-line biochemical screen. A total testosterone above 150-200 ng/dL in a reproductive-age woman should raise concern for an androgen-secreting tumor and warrants imaging.

Free testosterone is arguably the more clinically meaningful number because sex-hormone binding globulin (SHBG) determines how much testosterone is biologically active. Women with PCOS often have low SHBG (driven by insulin resistance), so free testosterone can be elevated even when total testosterone looks borderline normal.

When to Order Additional Tests

• LH and FSH: Useful if PCOS is suspected. A raised LH-to-FSH ratio (>2:1) supports but does not confirm PCOS.
• Fasting insulin and glucose: Insulin resistance amplifies androgen production in PCOS; up to 70% of women with PCOS have some degree of insulin resistance.
• Cortisol / 24-hour urine free cortisol: If Cushing syndrome is suspected (central weight gain, striae, proximal muscle weakness).
• Pelvic ultrasound: Assesses ovarian morphology and rules out a mass. Adrenal imaging (CT or MRI) is added if DHEA-S is markedly elevated or total testosterone exceeds 150 ng/dL.

Cycle Timing Matters

If you still have menstrual cycles, collect the blood draw on cycle days 2-5 (the early follicular phase). Testosterone and LH are most interpretable then. A draw in the luteal phase can give a falsely elevated progesterone and a misleadingly low LH. If your cycles are highly irregular (a common PCOS feature), draw fasting on any day but document the last menstrual period date.

Sex-Specific Physiology: Why Women Process Androgens Differently

Men and women share the same androgen receptors, but several physiological differences change how androgens behave in women.

SHBG binding: Women typically have higher SHBG than men, which buffers free testosterone. Conditions that lower SHBG (insulin resistance, hypothyroidism, obesity, certain progestins) effectively raise free androgen activity without changing total testosterone at all.

5-alpha reductase activity in skin: The skin of the face and the pubic region has higher 5-alpha reductase type 1 activity. This converts testosterone to DHT locally, amplifying the androgenic signal at the follicle independent of serum levels.

Menstrual cycle fluctuations: Testosterone peaks slightly around ovulation and rises again in the late luteal phase. Women who track symptoms carefully may notice that facial hair feels coarser or more noticeable in the week before their period, which reflects this cycle-driven variation.

Body composition effects: Adipose tissue is an active endocrine organ. Fat cells express aromatase (which converts androgens to estrogens) but also store and release free fatty acids that suppress SHBG production. Women with higher visceral adiposity tend to have both lower SHBG and higher free androgens, creating a self-reinforcing cycle.

Treatment Options: What the Evidence Shows

Lifestyle and Insulin Sensitization

For women with PCOS-related hirsutism and insulin resistance, weight loss of even 5-10% of body weight can lower free testosterone and improve menstrual regularity. A Cochrane systematic review found that combined lifestyle interventions reduced hirsutism scores significantly in overweight women with PCOS compared to no intervention.

Metformin at doses of 1,500-2,000 mg/day lowers insulin and modestly reduces androgen levels, but its effect on facial hair alone is smaller than that of hormonal therapies. It is most useful when insulin resistance is documented.

Hormonal Therapies

Combined oral contraceptives (COCs) are first-line for women who need contraception or do not want pregnancy. They work through two mechanisms: suppressing LH (and therefore ovarian testosterone production) and raising SHBG, which binds free testosterone. Pills containing drospirenone or norgestimate have the most favorable androgenic profiles. Allow at least 6 months before assessing hair response.

Spironolactone is the most widely used anti-androgen in the U.S. For hirsutism. At doses of 100-200 mg/day, it blocks the androgen receptor and weakly inhibits 5-alpha reductase. A randomized trial published in NEJM (2017) found that spironolactone 100 mg/day reduced acne lesion counts (a related androgen-driven outcome) significantly compared to placebo, supporting its broad anti-androgen activity.

The WomanRx Life-Stage Treatment Framework for Hirsutism:

| Life Stage | Preferred First-Line | Notes | |---|---|---| | Reproductive, not TTC | COC + spironolactone 100 mg/day | Contraception required with spironolactone | | Trying to conceive | Lifestyle, metformin, clomiphene for ovulation | Stop anti-androgens before attempting conception | | Pregnant | No medical anti-androgen therapy | Cosmetic hair removal only | | Postpartum/lactating | Cosmetic removal; defer systemic therapy | Spironolactone safety in lactation is not established | | Perimenopause | Low-dose COC or spironolactone; menopausal HT may stabilize | Discuss cardiovascular risk | | Post-menopause | Spironolactone or topical eflornithine; rule out tumor first | HT does not worsen hirsutism at standard doses |

Finasteride at 2.5-5 mg/day inhibits 5-alpha reductase and has shown efficacy comparable to spironolactone in several small trials. It is used off-label for hirsutism in women. Reliable contraception is mandatory (see pregnancy section below).

Topical eflornithine 13.9% cream (Vaniqa) slows facial hair growth by inhibiting ornithine decarboxylase in the follicle. It does not remove existing hair but reduces regrowth rate. It is FDA-approved specifically for facial hair reduction in women and can be combined with laser hair removal for faster cosmetic results.

Cosmetic and Procedural Options

Laser hair removal and intense pulsed light (IPL) are the most durable cosmetic options, but they require multiple sessions and work best on dark hair against light skin. Electrolysis is the only FDA-cleared method for permanent hair removal and works across all skin and hair types. Threading and waxing offer temporary results but do not worsen the underlying hormonal driver.

Pregnancy, Lactation, and Contraception: What You Must Know

This section is required reading before starting any medical treatment for facial hair.

Spironolactone: Contraindicated in Pregnancy

Spironolactone is an anti-androgen, and that is precisely the problem in pregnancy. Animal studies showed feminization of male fetuses; while human data is limited, the theoretical risk of disrupting normal androgen-mediated male fetal development is serious. The FDA classifies spironolactone as contraindicated in pregnancy. Any woman of reproductive age prescribed spironolactone must use effective contraception (an IUD, implant, or COC) throughout treatment. Stop spironolactone at least one month before attempting conception.

Lactation transfer of spironolactone is poorly studied. The active metabolite canrenone does appear in breast milk. Most clinicians advise against use while breastfeeding.

Finasteride: Teratogenic, Category X for Male Fetuses

Finasteride is classified as FDA Pregnancy Category X. Even handling crushed finasteride tablets is discouraged in pregnant women because dermal absorption could theoretically affect a male fetus. The drug label states that finasteride is contraindicated in women who are or may become pregnant. Two forms of contraception are recommended during use. Do not use while breastfeeding.

Combined Oral Contraceptives in Pregnancy

COCs should be stopped as soon as pregnancy is confirmed. While first-trimester inadvertent exposure has not been shown to cause fetal harm in large observational studies, COCs are not appropriate during pregnancy. They are generally considered compatible with a decision to breastfeed for women who are at least 6 weeks postpartum, though some guidelines suggest waiting until milk supply is established.

Safe Options During Pregnancy and Lactation

No systemic anti-androgen therapy is safe in pregnancy. Cosmetic hair removal (threading, waxing, laser if performed by an experienced practitioner) is the only option. Topical eflornithine has not been adequately studied in pregnancy or lactation and should be avoided.

If hirsutism develops acutely or worsens rapidly during pregnancy, see your provider promptly. Androgen-secreting tumors, luteomas of pregnancy, and theca-lutein cysts are rare but real causes that require evaluation.

Who This Is Right For (and Who Needs a Different Approach)

Good candidates for the standard workup and treatment path

• Women in their 20s-40s with gradual-onset facial hair, irregular periods, and signs of insulin resistance (PCOS is likely)
• Perimenopausal women with new chin or upper lip hair and no other symptoms (relative androgen excess from estrogen decline)
• Women with a known PCOS diagnosis seeking better symptom control

Seek urgent evaluation if

• Facial hair onset is sudden (weeks to months, not years)
• You also have a deepening voice, clitoral enlargement, or significant muscle mass increase (virilization)
• Total testosterone is above 150-200 ng/dL or DHEA-S is markedly elevated (possible tumor)
• You are post-menopausal and facial hair is new

Conditions that change the approach

Women with hypothyroidism should correct thyroid levels before starting anti-androgen therapy; TSH normalization alone sometimes reduces hirsutism. Women with hyperprolactinemia need prolactin treated first (usually with cabergoline or bromocriptine) because elevated prolactin drives androgen excess indirectly. Women with Cushing syndrome need the cortisol source treated, not anti-androgens.

What to Expect at Your Appointment

Bring a list of all medications, including herbal supplements (saw palmetto, DHEA, and tribulus terrestris all affect androgens). Photograph the affected areas before your visit with consistent lighting; this gives your clinician a baseline and helps track response to treatment over time.

Your clinician will likely calculate a modified Ferriman-Gallwey score, review your menstrual history, screen for signs of insulin resistance (acanthosis nigricans, waist circumference), and order the blood panel described above. ACOG recommends a pelvic ultrasound when PCOS is suspected, though it is not required to make the diagnosis.

Medical hair treatment takes time. The hair growth cycle runs approximately 6 months, so anti-androgen therapy must run at least that long before you can accurately judge whether it is working. Do not stop treatment at 8 weeks because you are not seeing results; that timeline is too short.